ArticleGenes & development2017
Oncogenic
Abstract read
In one paragraph
Article in Genes & development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed.
- Association of Maintenance Therapy Strategies with Survival Following First-Line Bevacizumab-Based Combination Chemotherapy in Metastatic Colorectal Cancer: A Single-Center Retrospective Observational Study.Journal of clinical medicine · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- The pro-inflammatory cytokines IFN-α and TNF-α inhibit organoid-derived extravillous trophoblast invasion.iScience · 2026Article
- Survival prediction of colorectal cancer using 101 machine learning methods based on immune-related genes: A machine learning study.Medicine · 2026Article
- Viral mimicry may help explain immunogenic cell death.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Claudin-1 Near-Infrared Fluorescent Antibody Conjugate for In Vivo Primary and Metastatic Colorectal Cancer Detection.Molecular imaging and biology · 2026Article
- Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer.NPJ precision oncology · 2026Article
- Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors.Journal of gastrointestinal cancer · 2026Article
- Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer.Cancer cell · 2026Article
- Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma.Scientific reports · 2026Article
- Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer.International journal of biological sciences · 2026Review
- P62 in colorectal cancer: from inflammation suppression to cancer promotion.Frontiers in immunology · 2026Review
- Comparative metabolomics reveals specific metabolic signatures in colorectal cancer cell line models.Discover oncology · 2025Article
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression.Cell death and differentiation · 2025Article
- WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer.EMBO reports · 2025Article
- Article
- Steroidal Alkaloids fromACS omega · 2025Article
- NOX1 and NPY1R mark regional colon stem cell populations that serve as cancer origins in vivo.Nature cell biology · 2025Article
- Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Adam T BoutinDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Wen-Ting LiaoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Melody WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Soyoon Sarah HwangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Tatiana V KarpinetsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Hannah CheungDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Gerald C ChuInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Shan JiangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Jian HuDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Kyle ChangDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Eduardo VilarDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Xingzhi SongInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Jianhua ZhangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Y Alan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Lawrence N KwongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Funding
TELOMERASE IN DEVELOPMENT, SENESCENCE AND NEOPLASIAR01CA084628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2000 to 2019
$10.5MNCI NIH HHS R01 CA084628
Abstract
Human colorectal cancer (CRC) is a major cause of cancer mortality and frequently harbors activating mutations in the
Indexed as
AnimalsCell Line, TumorColorectal NeoplasmsDisease Models, AnimalGenotypeHumansMiceMice, Inbred C57BLMutationNeoplasm InvasivenessNeoplasm MetastasisProto-Oncogene Proteins p21(ras)TranscriptomeTransforming Growth Factor betaHras protein, mouseProto-Oncogene Proteins p21(ras)Transforming Growth Factor betaApccolorectal cancerinvasionKrasmetastasisP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.